Jarushka Naidoo shared on X:

“Pooled 5-yr outcomes of Pembrolizumab and Chemotherapy  for PDL1<1% metastatic Non-Small Cell Lung Cancer (NSCLC) in the Journal of Thoracic Oncology.

• 442 patients (KN189, KN407 and China/Japan extensions).
•  mOS 0.64, mPFS HR 0.66, 5yr OS 12.5 v 9.3% favors chemo-IO.
•  g3 and TRAEs 59.1% chemo-IO.”

Additional information.
Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.